Sugi Predict

Sugi Predict / Compounds / SCHEMBL3396199

SCHEMBL3396199

SCHEMBL3396199

Cc1cc(Nc2ncc3ccn(-c4cc(F)c(CN5CCOCC5)c(F)c4)c3n2)cc(C)c1OCCN1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 4/20 0.51
▸ SYK P43405 2/20 0.48
▸ STAT6 P42226 5/20 0.42
▸ PTK2 Q05397 7/20 0.42
▸ LCK P06239 2/20 0.41
▸ KDR P35968 2/20 0.41
▸ SRC P12931 1/20 0.41
▸ AURKA O14965 2/20 0.40
▸ JAK2 O60674 2/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ PAK4 O96013 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ FYN P06241 1/20 0.40
▸ CSF1R P07333 1/20 0.40
▸ RET P07949 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ MET P08581 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ FGFR1 P11362 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1655193 0.94 RPS6KA3 (0.48) RPS6KA3SYKSTAT6PTK2LCK
SCHEMBL1655189 0.94 RPS6KA3 (0.46) RPS6KA3SYKSTAT6PTK2LCK
SCHEMBL1655869 0.87 RPS6KA3 (0.54) RPS6KA3STAT6SRCAURKAJAK2
SCHEMBL1655295 0.87 RPS6KA3 (0.54) RPS6KA3STAT6AURKAJAK2JAK3
SCHEMBL1656206 0.86 RPS6KA3 (0.50) RPS6KA3SYKSTAT6AURKAJAK2
SCHEMBL1655369 0.86 RPS6KA3 (0.49) RPS6KA3SYKSTAT6AURKAJAK2
SCHEMBL1657475 0.85 RPS6KA3 (0.55) RPS6KA3STAT6PTK2AURKAJAK2
SCHEMBL1655191 0.84 RPS6KA3 (0.47) RPS6KA3SYKSTAT6PTK2LCK
SCHEMBL1654946 0.84 RPS6KA3 (0.52) RPS6KA3SYKSTAT6SRCAURKA
SCHEMBL1655241 0.83 RPS6KA3 (0.54) RPS6KA3STAT6AURKAJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 — — EP claimed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US claimed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 — — WO claimed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 RPS6KA3 303/4885SYK 90/4885STAT6 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.